IL110309A0 - A method of protecting against neuron loss - Google Patents

A method of protecting against neuron loss

Info

Publication number
IL110309A0
IL110309A0 IL11030994A IL11030994A IL110309A0 IL 110309 A0 IL110309 A0 IL 110309A0 IL 11030994 A IL11030994 A IL 11030994A IL 11030994 A IL11030994 A IL 11030994A IL 110309 A0 IL110309 A0 IL 110309A0
Authority
IL
Israel
Prior art keywords
vitamin
compound
neuron loss
against neuron
protect against
Prior art date
Application number
IL11030994A
Other languages
English (en)
Original Assignee
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kentucky Res Found filed Critical Univ Kentucky Res Found
Publication of IL110309A0 publication Critical patent/IL110309A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Signal Processing For Digital Recording And Reproducing (AREA)
  • Moving Of Heads (AREA)
IL11030994A 1993-07-15 1994-07-13 A method of protecting against neuron loss IL110309A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9197693A 1993-07-15 1993-07-15

Publications (1)

Publication Number Publication Date
IL110309A0 true IL110309A0 (en) 1994-10-21

Family

ID=22230588

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11030994A IL110309A0 (en) 1993-07-15 1994-07-13 A method of protecting against neuron loss

Country Status (10)

Country Link
US (1) US5939407A (fr)
EP (1) EP0710112B1 (fr)
JP (1) JPH09507830A (fr)
AT (1) ATE209921T1 (fr)
AU (1) AU7333694A (fr)
CA (1) CA2167171C (fr)
DE (1) DE69429351T2 (fr)
ES (1) ES2166377T3 (fr)
IL (1) IL110309A0 (fr)
WO (1) WO1995002409A2 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010012770A (ko) 1997-05-22 2001-02-26 세파론, 인코포레이티드 비타민 ｄ 유사체 및 그 뉴런 효과
WO1999059596A1 (fr) * 1998-05-15 1999-11-25 The Board Of Trustees Of Leland Stanford Junior University Antagonistes du recepteur de glucocorticoide aux fins du traitement de la demence
EP1280546A4 (fr) * 2000-05-09 2005-02-23 Childrens Medical Center Methode et composition destinees au traitement de l'angiogenese
US7256184B2 (en) * 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
US7858602B2 (en) * 2000-10-16 2010-12-28 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells
WO2002036605A2 (fr) * 2000-11-03 2002-05-10 Washington University Structures de cycles aromatiques modifies a substitution hydroxy et a activite cytoprotectrice
AU2002228891A1 (en) * 2000-11-17 2002-05-27 Washington University Cytoprotective estrogen derivatives
JP2005512949A (ja) * 2001-05-04 2005-05-12 コーセプト セラピューティクス， インコーポレイテッド グルココルチコイドレセプターに特異的なアンタゴニストを使用して、せん妄を処置する方法
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20050192255A1 (en) * 2003-07-30 2005-09-01 Jin Tian Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease
WO2005116047A2 (fr) * 2004-05-27 2005-12-08 Migenix Corp. Composes et methodes de cytoprotection
WO2006125324A1 (fr) * 2005-05-27 2006-11-30 Queen's University At Kingston Traitement de troubles du repliement des proteines
JP2007023010A (ja) * 2005-07-19 2007-02-01 Toshiro Azegami 閉経後のホルモンバランス調整及びパーキンソン症の予防改善目的の経口組成物
ES2645816T3 (es) * 2006-04-03 2017-12-07 Accera, Inc. Uso de compuestos cetogénicos para el tratamiento de la alteración de la memoria asociada a la edad
US20100204192A1 (en) * 2007-06-11 2010-08-12 University Of Sourthern California Agents, compositions and methods for enhancing neurological function
US8969329B2 (en) * 2007-06-11 2015-03-03 University Of Southern California Allopregnanolone in a method for enhancing neurological function
US20110306579A1 (en) * 2009-01-30 2011-12-15 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
EP2363119A1 (fr) * 2010-03-05 2011-09-07 Centre Hospitalier Universitaire d'Angers Nouvelle composition pharmaceutique utile pour le traitement des personnes affectées par des maladies neurodégénératives ou neurovasculaires
FR2965178B1 (fr) * 2010-09-29 2012-10-05 Sebastien Lasnier Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimer
DK2753632T3 (da) 2011-09-08 2023-07-10 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelse heraf
ES2886506T3 (es) 2013-03-13 2021-12-20 Sage Therapeutics Inc Esteroides neuroactivos
EP2988618A1 (fr) 2013-03-27 2016-03-02 DSM IP Assets B.V. Utilisation de 25-hydroxyvitamine d3 pour améliorer les fonctions exécutives
US20140296190A1 (en) * 2013-03-27 2014-10-02 Dsm Ip Assets B.V. Marketing the use of 25-hydroxyvitamin d3 to enhance cognition
ES2536256B2 (es) * 2013-11-20 2016-02-01 Universidade De Santiago De Compostela Análogos de vitamina d con interés farmacéutico
WO2015195967A1 (fr) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxystérols et leurs procédés d'utilisation
HUE055199T2 (hu) 2015-07-06 2021-11-29 Sage Therapeutics Inc Oxiszterolok és alkalmazási eljárásaik
AU2016289967B2 (en) 2015-07-06 2021-09-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
JP6882996B2 (ja) 2015-07-06 2021-06-02 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
SI3436022T1 (sl) 2016-04-01 2022-08-31 Sage Therapeutics, Inc. Oksisteroli in postopki za uporabo le-teh
WO2017193046A1 (fr) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxystérols et méthodes d'utilisation associées
MA45598B1 (fr) 2016-07-07 2021-09-30 Sage Therapeutics Inc Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
CA3038900A1 (fr) 2016-09-30 2018-04-05 Sage Therapeutics, Inc. Oxysterols substitues en c7 et procedes en tant que modulateurs nmda
TWI815800B (zh) 2016-10-18 2023-09-21 美商賽吉醫療公司 氧固醇(oxysterol)及其使用方法
EP3529256B1 (fr) 2016-10-18 2023-08-09 Sage Therapeutics, Inc. Oxystérols et leurs procédés d'utilisation
WO2021217086A1 (fr) 2020-04-24 2021-10-28 The Johns Hopkins University Compositions et méthodes comprenant des dendrimères et des agents thérapeutiques
WO2023028554A1 (fr) 2021-08-25 2023-03-02 Neuraly, Inc. Agonistes de glp-1r destinés à être utilisés dans le traitement d'une déficience neurologique associée à une infection virale

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63104926A (ja) * 1986-10-21 1988-05-10 Teijin Ltd 老年性痴呆症治療又は予防剤
FR2639225B1 (fr) * 1988-11-21 1993-05-21 Centre Nat Rech Scient Compositions pharmaceutiques pour la neuroprotection contenant des arylcyclohexylamines
US4897388A (en) * 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
US4957909A (en) * 1989-05-04 1990-09-18 American Home Products Corporation Benzobicycloalkane derivatives as anticonvulsant neuroprotective agents
US5089517A (en) * 1990-08-03 1992-02-18 The Board Of Trustees Of The Leland Stanford Junior University Neuroprotection by indolactam v and derivatives thereof
US5168103A (en) * 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
US5196421A (en) * 1991-06-05 1993-03-23 Eli Lilly And Company Excitatory amino acid receptor antagonists in methods for the use thereof
US5153196A (en) * 1991-06-05 1992-10-06 Eli Lilly And Company Excitatory amino acid receptor antagonists and methods for the use thereof

Also Published As

Publication number Publication date
ATE209921T1 (de) 2001-12-15
EP0710112B1 (fr) 2001-12-05
JPH09507830A (ja) 1997-08-12
EP0710112A1 (fr) 1996-05-08
DE69429351T2 (de) 2002-05-23
CA2167171A1 (fr) 1995-01-26
CA2167171C (fr) 2007-04-24
WO1995002409A2 (fr) 1995-01-26
US5939407A (en) 1999-08-17
WO1995002409A3 (fr) 1995-04-27
ES2166377T3 (es) 2002-04-16
AU7333694A (en) 1995-02-13
DE69429351D1 (de) 2002-01-17

Similar Documents

Publication Publication Date Title
IL110309A0 (en) A method of protecting against neuron loss
WO1996012697A3 (fr) Composes capables de moduler l'activite du recepteur de calcium
NZ328898A (en) Sustained release formulation containing collagen and glycosaminoglycan additives
PT1156043E (pt) Drogas que aumentam as respostas sinapticas mediadas por receptores de ampa
MD895B2 (ro) Preparat sinergetic şi procedeu de distrugere selectivă a buruienilor
EP0744942A4 (fr) Composition sous forme d'hydrogel a liberation prolongee regulee
TW326394B (en) Insulin formulation
CA2117532A1 (fr) Methode d'inhibition de la cancerogenese par traitement au moyen de la dehydroepiandrosterone et de ses analogues
AU1876788A (en) Methylene phosphonoalkylphosphinates, pharmaceutical compositions , and methods for treating abnormal calcium and phosphate metabolism
GB2223403B (en) Inositoltrisphosphate for the treatment of disorders related to transplantation
HU9301578D0 (en) Fungicidal preparatives containing 1-aryl-3-(3,4-dihydro-4-oxo-3-quinazolinyl)-urea as active substance
NO994395L (no) Stabilt, fast preparat som inneholder vitamin D3 og trikalsiumfosfat
MX9705806A (es) Forma farmaceutica destinada a la cesion de colagenasa en heridas, y procedimiento para su elaboracion.
DE69314463D1 (de) Hautregenerierende kosmetische zusammensetzung
WO1990001321A3 (fr) Procede de traitement et de prevention de la perte de masse osseuse
BR9811829A (pt) Processos para fumegação do solo contendo organismos deletérios controlando ao mesmo tempo a fitotoxicidade, e, para controlar organismos deletérios no solo
BR9707770C1 (pt) Tifluzamida com eficácia aperfeiçoada
NZ214103A (en) Antimicrobial composition; synergistic mixture of maduramicin and nicarbazin
DK0575974T3 (fr)
ES2078319T3 (es) Composiciones que contienen inhibidores de aldosa reductasa para el tratamiento de ulceras.
IL96506A0 (en) Transdermal system for administering pharmaceutical compounds under ph control
MX9302986A (es) Medicamento que contiene metrifonato y procedimiento para su preparacion
HK1016067A1 (en) Topical bisphosphonates for prevention of bone resorption
DE69628430D1 (de) Verwendung von lactoferrin zur prävention des nachoperativen astigmatismus
ES8404182A1 (es) Un metodo de prepara el enantiomero (+) s de secoverin